Distinct histone modifications denote early stress-induced drug tolerance in cancer

Besides somatic mutations or drug efflux, epigenetic reprogramming can lead to acquired drug resistance. We recently have identified early stress-induced multi-drug tolerant cancer cells termed induced drug-tolerant cells (IDTCs). Here, IDTCs were generated using different types of cancer cell lines; melanoma, lung, breast and colon cancer. A common loss of the H3K4me3 and H3K27me3 and gain of H3K9me3 mark was observed as a significant response to drug exposure or nutrient starvation in IDTCs. These epigenetic changes were reversible upon drug holidays. Microarray, qRT-PCR and protein expression data confirmed the up-regulation of histone methyltransferases (SETDB1 and SETDB2) which contribute to the accumulation of H3K9me3 concomitantly in the different cancer types. Genome-wide studies suggest that transcriptional repression of genes is due to concordant loss of H3K4me3 and regional increment of H3K9me3. Conversely, genome-wide CpG site-specific DNA methylation showed no common changes at the IDTC state. This suggests that distinct histone methylation patterns rather than DNA methylation are driving the transition from parental to IDTCs. In addition, silencing of SETDB1/2 reversed multi drug tolerance. Alterations of histone marks in early multi-drug tolerance with an increment in H3K9me3 and loss of H3K4me3/H3K27me3 is neither exclusive for any particular stress response nor cancer type specific but rather a generic response.

[1]  D. Hoon,et al.  Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer , 2017, Genomics data.

[2]  B. Vick,et al.  Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia , 2016, Nature Medicine.

[3]  L. Qiu,et al.  PHF19 Promotes Drug Resistance through EZH2 Inactivation in Multiple Myeloma , 2016 .

[4]  Matt van de Rijn,et al.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival , 2016, Modern Pathology.

[5]  Fan Liu,et al.  Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape , 2016, Nature Reviews Cancer.

[6]  G. Mills,et al.  Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. , 2016, The Journal of clinical investigation.

[7]  Toshihiro Ito,et al.  Type I Interferon Induced Epigenetic Regulation of Macrophages Suppresses Innate and Adaptive Immunity in Acute Respiratory Viral Infection , 2015, PLoS pathogens.

[8]  Jeong-Hyeon Choi,et al.  H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance , 2015, The Journal of Immunology.

[9]  Chunbo He,et al.  Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer , 2015, Tumor Biology.

[10]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[11]  D. Morton,et al.  Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome , 2015, Pigment cell & melanoma research.

[12]  H P Soyer,et al.  A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.

[13]  K. Mechtler,et al.  H3S28 phosphorylation is a hallmark of the transcriptional response to cellular stress , 2014, Genome research.

[14]  Fidel Ramírez,et al.  deepTools: a flexible platform for exploring deep-sequencing data , 2014, Nucleic Acids Res..

[15]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[16]  P. Ascierto,et al.  Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy , 2014, British Journal of Cancer.

[17]  R. Xia,et al.  High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. , 2013, Archives of pathology & laboratory medicine.

[18]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[19]  Daniel J. Sargent,et al.  Drug rechallenge and treatment beyond progression—implications for drug resistance , 2013, Nature Reviews Clinical Oncology.

[20]  D. Green,et al.  The Cul4A–DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity , 2013, Oncogene.

[21]  H. Ng,et al.  Genome-wide kinase-chromatin interactions reveal the regulatory network of ERK signaling in human embryonic stem cells. , 2013, Molecular cell.

[22]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[23]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[24]  Yong Zhang,et al.  Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.

[25]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[26]  J. Burke,et al.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Steven J. M. Jones,et al.  DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. , 2011, Cell stem cell.

[28]  G. Pfeifer,et al.  Relationship between Gene Body DNA Methylation and Intragenic H3K9me3 and H3K36me3 Chromatin Marks , 2011, PloS one.

[29]  David A. Orlando,et al.  The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset , 2011, Nature.

[30]  W. J. Kent,et al.  BigWig and BigBed: enabling browsing of large distributed datasets. , 2010, Bioinformatics.

[31]  Anne H. O'Donnell,et al.  Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. , 2010, Genome research.

[32]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[33]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[34]  G. Almouzni,et al.  The HP1α–CAF1–SetDB1‐containing complex provides H3K9me1 for Suv39‐mediated K9me3 in pericentric heterochromatin , 2009, EMBO reports.

[35]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[36]  J. Herman,et al.  Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. , 2009, Carcinogenesis.

[37]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[38]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[39]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[40]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[41]  M. Hung,et al.  Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.

[42]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[43]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[44]  Rainer Breitling,et al.  Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments , 2004, FEBS letters.

[45]  Bernard Roizman,et al.  STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Fojo,et al.  Strategies for reversing drug resistance , 2003, Oncogene.

[47]  T. Jenuwein,et al.  Suv39h-Mediated Histone H3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin , 2003, Current Biology.

[48]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[49]  E. Selker,et al.  Emerging connections between DNA methylation and histone acetylation , 2001, Cellular and Molecular Life Sciences CMLS.

[50]  T. Dryja,et al.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. , 1991, American journal of human genetics.

[51]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[52]  M. Fukuoka,et al.  Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  M. Lind,et al.  Do beta-tubulin mutations have a role in resistance to chemotherapy? , 2004, The Lancet. Oncology.

[54]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[55]  I. Tannock,et al.  Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.